Evive

Evive Biotech is a global biopharmaceutical company focused on developing innovative biologic therapies for oncology and inflammatory diseases. The company's lead product, Ryzneuta (efbemalenograstim alfa), is a novel long-acting granulocyte colony-stimulating factor (G-CSF) approved by the FDA and EMA for the treatment of chemotherapy-induced neutropenia. Evive utilizes its proprietary DiKine platform to develop a pipeline of therapeutic proteins and antibodies with enhanced efficacy and safety profiles. Headquartered in Singapore with R&D and manufacturing facilities in China and the US, the company operates as the biologics arm of Yifan Pharmaceutical. Evive made history as the first Chinese biotech to receive FDA approval for a novel biologic developed independently from discovery through clinical trials.